Upon completion of the chapter, the reader will be able to:
Identify risk factors for multiple sclerosis (MS).
Describe pathophysiologic findings of MS.
Distinguish between forms of MS based on patient presentation and disease course.
Compare and contrast MS disease-modifying treatment choices for a given patient.
Determine appropriate symptomatic treatment choices for a given patient.
Develop a monitoring plan for a patient placed on specific medications.
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS), variable in symptoms and presentation. Multiple describes the number of CNS lesions, and sclerosis refers to the demyelinated lesions, today called plaques.
EPIDEMIOLOGY AND ETIOLOGY
Approximately 2.3 million people worldwide have MS.1 Diagnosis usually occurs between 20 and 50 years, affecting twice as many women as men.1 Whites and people of northern European heritage are more likely to develop MS; prevalence decreases with decrease in latitude.1,2 Risk factors include family history of MS, autoimmune diseases, or migraine; personal history of autoimmune diseases or migraine; and, in women, cigarette smoke exposure.
Family members of MS patients have a 5% risk; monozygotic twins have a concordance rate of 25% to 30%.2 Genetics cannot fully explain the etiology of MS because only a small proportion of patients report a family member with MS; however, genetic risks may explain up to 35% of cases.3
Epstein-Barr virus is thought to be a possible infectious etiologic agent.3 Infection cannot fully explain MS because there is a high rate of seropositivity in the population, but MS is much less common. Other environmental theories involve decreased patient or maternal vitamin D serum concentrations or high sodium consumption.2,3
While the causative agent of MS is unclear, the result is the development of an autoimmune disorder with areas of CNS inflammation and degeneration.
An unknown antigen presented by the major histocompatibility complex (MHC) class II molecules causes T-cells to become autoreactive (Figure 30–1). Autoreactive T-cells enter lymphatic tissues to expand. Upon a signal involving sphingosine-1-phosphate, T-cells reenter the circulation.4 Once activated, T-cells attach to upregulated adhesion molecules and produce matrix metalloproteinases (MMP) that cause blood–brain barrier breakdown. In the CNS, T-cells come into contact with antigen-presenting cells and proliferate. The T-helper cells differentiate into proinflammatory T-helper-1 cells (Th1 cells) and anti-inflammatory T-helper-2 cells (Th2 cells).4 Th1 cells secrete cytokines that enhance macrophage and microglial cells that attack myelin.4
Autoimmune theory of the pathogenesis of MS. In MS, the immunogenic cells tend to be more myelin-reactive, and these T-cells produce cytokines ...
Log In to View More
If your institution is currently a subscriber
of Pharmacotherapy Principles & Practice please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.